SAGE News and Press, Sage Therapeutics Inc. From 02/06/23

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWI...

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need Sage Therapeutics, Inc. (Nasdaq: SAGE) and ...

Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m. ET to review fourth quarter and full year 2022 financial results and discuss...

Sage Therapeutics ( NASDAQ: SAGE ) said that its experimental oral therapy for major depressive disorder and postpartum depression, zuranolone, could become available as early as Q3. The company anticipates the US FDA will accept its rolling New Drug Application, completed in Decemb...

Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as the third quarter of 2023 if priority review is re...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. PT in San Francisco, ...

Summary Sage Therapeutics, Inc. completed its rolling submission to the FDA for zuranolone in two indications. Zuranolone is a better formulation of Sage Therapeutics' marketed postpartum drug. However, clinical experience on the major depression side is shaky. ...

Summary SAGE's collaboration with BIIB looks to be finally building momentum around the zuranolone segment. It is set to be selling into a broad set of growing end-markets. The recent new drug administration is a good step forward and sets the company up for the next stages of comme...

Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD) Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug A...